Abstract:Background TREM2 is a microglial receptor genetically linked to the risk for Alzheimer’s disease (AD). The cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2) have emerged as a valuable biomarker for the disease progression in AD and higher CSF levels of sTREM2 are linked to slower cognitive decline. Increasing sTREM2 in mouse models of amyloidosis reduces amyloid-related pathology through modulating microglial functions, suggesting a beneficial role of sTREM2 in microglia biology and AD pathology. Methods In the current study, we performed serial C- and N-terminal truncations of sTREM2 protein to define the minimal sequence requirement for sTREM2 function. We initially assessed the impacts of sTREM2 mutants on microglial functions by measuring cell viability and inflammatory responses. The binding of the sTREM2 mutants to oligomeric Aβ was determined by solid-phase protein binding assay and dot blot assay. We further evaluated the impacts of sTREM2 mutants on amyloid-related pathology by direct stereotaxic injection of sTREM2 proteins into the brain of 5xFAD mice. Results We found that both sTREM2 fragments 41–81 and 51–81 enhance cell viability and inflammatory responses in primary microglia. However, the fragment 51–81 exhibited impaired affinity to oligomeric Aβ. When administrated to the 5xFAD mice brain, the sTREM2 fragment 41–81, but not 51–81, increased the number of plaque-associated microglia and reduced the plaque deposition. Interestingly, the fragment 41–81 was more efficient than the physiological form of sTREM2 in ameliorating Aβ-related pathology. Conclusions Our results indicate that the interaction of sTREM2 truncated variants with Aβ is essential for enhancing microglial recruitment to the vicinity of an amyloid plaque and reducing the plaque load. Importantly, we identified a 41-amino acid sequence of sTREM2 that is sufficient for modulating microglial functions and more potent than the full-length sTREM2 in reducing the plaque load and the plaque-associated neurotoxicity. Taken together, our data provide more insights into the mechanisms underlying sTREM2 function and the minimal active sTREM2 sequence represents a promising candidate for AD therapy.

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease.

TREM2 and the Progression of Alzheimer’s Disease

Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model

TREMs in Alzheimer's Disease: Genetic and Clinical Investigations

TREMs in Alzheimer's disease: Genetic and clinical investigations.

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

TREM2 Ectodomain and Its Soluble Form in Alzheimer’s Disease

TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism.

A systematic review of the role of TREM2 in Alzheimer's disease

TREM2 in Alzheimer’s Disease

Soluble TREM2 Induces Inflammatory Responses and Enhances Microglial Survival

Decoding sTREM2: its impact on Alzheimer's disease – a comprehensive review of mechanisms and implications

TREM2 Regulates Innate Immunity in Alzheimer’s Disease

Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

The Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target

Identification of the Minimal Active Soluble TREM2 Sequence for Modulating Microglial Phenotypes and Amyloid Pathology

Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease.

TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment

Recent Advances in Triggering Receptor Expressed in Myeloid 2 and Its Role in Alzheimer's Disease

Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis